213 related articles for article (PubMed ID: 26053201)
21. Functional characterization of the novel T599I-VKSRdel BRAF mutation in a follicular variant papillary thyroid carcinoma.
De Falco V; Giannini R; Tamburrino A; Ugolini C; Lupi C; Puxeddu E; Santoro M; Basolo F
J Clin Endocrinol Metab; 2008 Nov; 93(11):4398-402. PubMed ID: 18697864
[TBL] [Abstract][Full Text] [Related]
22. Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder.
Boulalas I; Zaravinos A; Delakas D; Spandidos DA
Int J Biol Markers; 2009; 24(1):17-21. PubMed ID: 19404918
[TBL] [Abstract][Full Text] [Related]
23. Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E.
Jarry A; Masson D; Cassagnau E; Parois S; Laboisse C; Denis MG
Mol Cell Probes; 2004 Oct; 18(5):349-52. PubMed ID: 15294323
[TBL] [Abstract][Full Text] [Related]
24. Prevalence, tumorigenic role, and biochemical implications of rare BRAF alterations.
Barollo S; Pezzani R; Cristiani A; Redaelli M; Zambonin L; Rubin B; Bertazza L; Zane M; Mucignat-Caretta C; Bulfone A; Pennelli G; Casal Ide E; Pelizzo MR; Mantero F; Moro S; Mian C
Thyroid; 2014 May; 24(5):809-19. PubMed ID: 24295088
[TBL] [Abstract][Full Text] [Related]
25. Analysis of the BRAF V600E mutation in primary cutaneous melanoma.
Inumaru JS; Gordo KI; Fraga Junior AC; Silva AM; Leal CB; Ayres FM; Wastowski IJ; Borges NF; Saddi VA
Genet Mol Res; 2014 Jan; 13(2):2840-8. PubMed ID: 24535907
[TBL] [Abstract][Full Text] [Related]
26. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.
Agaimy A; Terracciano LM; Dirnhofer S; Tornillo L; Foerster A; Hartmann A; Bihl MP
J Clin Pathol; 2009 Jul; 62(7):613-6. PubMed ID: 19561230
[TBL] [Abstract][Full Text] [Related]
27. Hotspot mutations of BRAF gene are not associated with pediatric solid neoplasms.
Miao J; Kusafuka T; Fukuzawa M
Oncol Rep; 2004 Dec; 12(6):1269-72. PubMed ID: 15547749
[TBL] [Abstract][Full Text] [Related]
28. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
[TBL] [Abstract][Full Text] [Related]
29. The \textit{BRAF} V600E mutation in single- institution study of Russian melanoma patients.
Lyubchenko L; Emelyanova M; Shamanin V; Demidov L; Zasedatelev A; Nasedkina T
Cancer Biomark; 2016; 16(1):153-60. PubMed ID: 26600396
[TBL] [Abstract][Full Text] [Related]
30. BRAF mutations in metastatic melanoma: a possible association with clinical outcome.
Kumar R; Angelini S; Czene K; Sauroja I; Hahka-Kemppinen M; Pyrhönen S; Hemminki K
Clin Cancer Res; 2003 Aug; 9(9):3362-8. PubMed ID: 12960123
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas.
Nakayama H; Yoshida A; Nakamura Y; Hayashi H; Miyagi Y; Wada N; Rino Y; Masuda M; Imada T
Anticancer Res; 2007; 27(5B):3645-9. PubMed ID: 17972530
[TBL] [Abstract][Full Text] [Related]
32. Identification of frequent BRAF copy number gain and alterations of RAF genes in Chinese prostate cancer.
Ren G; Liu X; Mao X; Zhang Y; Stankiewicz E; Hylands L; Song R; Berney DM; Clark J; Cooper C; Lu YJ
Genes Chromosomes Cancer; 2012 Nov; 51(11):1014-23. PubMed ID: 22833462
[TBL] [Abstract][Full Text] [Related]
33. BRAF and KRAS mutations in stomach cancer.
Lee SH; Lee JW; Soung YH; Kim HS; Park WS; Kim SY; Lee JH; Park JY; Cho YG; Kim CJ; Nam SW; Kim SH; Lee JY; Yoo NJ
Oncogene; 2003 Oct; 22(44):6942-5. PubMed ID: 14534542
[TBL] [Abstract][Full Text] [Related]
34. Quantification of BRAF V600E alleles predicts papillary thyroid cancer progression.
Kim MH; Bae JS; Lim DJ; Lee H; Jeon SR; Park GS; Jung CK
Endocr Relat Cancer; 2014; 21(6):891-902. PubMed ID: 25266729
[TBL] [Abstract][Full Text] [Related]
35. BRAF V600E mutation-specific antibody: A review.
Ritterhouse LL; Barletta JA
Semin Diagn Pathol; 2015 Sep; 32(5):400-8. PubMed ID: 25744437
[TBL] [Abstract][Full Text] [Related]
36. Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma.
Santarpia L; Sherman SI; Marabotti A; Clayman GL; El-Naggar AK
Hum Pathol; 2009 Jun; 40(6):827-33. PubMed ID: 19200582
[TBL] [Abstract][Full Text] [Related]
37. BRAF V600E Mutations in Endometrial Adenocarcinoma.
He M; Breese V; Hang S; Zhang C; Xiong J; Jackson C
Diagn Mol Pathol; 2013 Mar; 22(1):35-40. PubMed ID: 23370429
[TBL] [Abstract][Full Text] [Related]
38. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
39. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.
Schmid K; Oehl N; Wrba F; Pirker R; Pirker C; Filipits M
Clin Cancer Res; 2009 Jul; 15(14):4554-60. PubMed ID: 19584155
[TBL] [Abstract][Full Text] [Related]
40. BRAF and KRAS mutations in prostatic adenocarcinoma.
Cho NY; Choi M; Kim BH; Cho YM; Moon KC; Kang GH
Int J Cancer; 2006 Oct; 119(8):1858-62. PubMed ID: 16721785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
